|
|
||||||||
RESEARCH COMMUNICATION |
a Institute of Bioengineering and Department of Physiology, Miguel Hernández University, San Juan Campus, Alicante, Spain
| ABSTRACT |
|---|
|
|
|---|
Key Words: intracellular calcium KATP channels insulin secretion confocal microscopy membrane estrogen receptor.
| INTRODUCTION |
|---|
|
|
|---|
Some recent observations strongly suggest that estrogens may have an in vivo insulinotropic effect. For instance, estradiol has been shown to reverse the effects of menopause on glucose and insulin metabolism, resulting in an increase in pancreatic insulin secretion and a decrease in insulin resistance (10, 11). Treatment of male and ovariectomized female mice with estrogen prevents the development of diabetes (12). Moreover, development of diabetes mellitus after major resection of the pancreas can be markedly prevented with estrogen administration due to improvement in insulin secretion and glucose tolerance (13). In spite of this circumstantial evidence, a direct effect of 17ß-estradiol upon ß-cells has yet to be demonstrated.
We demonstrate here a rapid insulinotropic effect of 17ß-estradiol due to regulation of KATP channel activity and calcium signals through a membrane receptor.
| METHODS |
|---|
|
|
|---|
Membrane potential measurement
The ß-cell membrane potential was recorded using high-resistance microelectrodes, essentially as described (14). Once microdissected, islets were placed in a 50 µl chamber perfused with fresh modified Krebs medium and constantly gassed with a mixture of 95% O2 and 5% CO2 for a final pH of 7.4. Temperature was maintained at 36°C. ß-Cells were impaled using thick-walled, high-resistance microelectrodes and recordings were made with an Axoclamp 2B amplifier (bridge mode). Data acquisition was performed with Axoscope1.1.
Intracellular calcium measurement
Whole islet of Langerhans isolated with collagenase were loaded with Indo-1 by incubation with the AM ester (5 µM, Molecular Probes, Eugene, Oreg.) for 4590 min at room temperature before measuring intracellular calcium using a double emission microfluorescence system (15).
Insulin secretion
Static incubation was conducted using batches of three islets each and incubated for 20 min at 37°C, pH 7.4, in 1 ml Krebs-Ringer buffer containing 1% bovine serum albumin (BSA) plus appropriate stimuli. At the end of each incubation, insulin was determined by radioimmunoassay (Diagnostic Products, Los Angeles, Calif.). Intraassay variation coefficient oscillated between 13% at 5 µIU/ml and 5% at insulin concentrations between 15 and 400 µIU/ml. Interassay variation coefficient was 7% at a detection limit of 1.2 µIU/ml.
Patch-clamp recording
Islets were dispersed into single cells and cultured as previously described (16). Patch pipettes were filled with a standard solution (in mM): KCl 140, HEPES 10, CaCl2 2, MgCl2 2; pH 7.4. Bath solution contained (in mM): KCl 5, NaCl 135, CaCl2 2.5, HEPES 10, MgCl2 1.1; pH 7.4. Solutions used for the inside-out experiments were (in mM): KCl 5, NaCl 135, HEPES 10, CaCl2 2.5, MgCl2 2.5, pH 7.4; for pipette, the solution contained (in mM): KCl 140, CaCl2 1, MgCl2 1, HEPES 10, EGTA 1; pH 7.2. KATP channel activity was quantified by digitizing 30 s sections of the current record, filtered at 3 kHz and sampled at 10 kHz by a Digidata 1200 (Axon Instruments), and calculating the mean NPo during the sweep (n=5). Experiments were carried out at room temperature (2024°C). Data are expressed as mean ± SD.
Assay for estradiol-peroxidase binding
Pancreatic islets cells cultured on polylysine-coated coverslips for 5 h were fixed in 4% (wt/vol) paraformaldehyde for 30 s and exposed overnight to 4.5 µg/ml estradiol-peroxidase. Cells were then washed and peroxidase was developed using 0.5 mg/ml 3,3'-diaminobenzidine (DAB) in the presence of 0.075% (vol/vol) H2O2 for 5 min. Cells were visualized using a Leica DMRB microscope.
Plasma membrane permeability assay
Cells were incubated with 2.5 mg/ml dextran-conjugated tetramethylrhodamine (dextran-TMR) and immediately visualized using a Zeiss LSM510 confocal microscope with a Zeiss 63x oil immersion lens, numerical aperture 1.3. The optical section was always lower than 600 nm. Results are representative of at least 50 cells in 3 different coverslips from 2 different experiments.
Location of estradiol-peroxidase binding
Confocal reflective microscopy
Once peroxidase assay was completed as described above, DAB precipitate was visualized using the reflective mode of conventional confocal microscopy.
Immunofluorescence
Peroxidase was labeled with rabbit anti-horseradish peroxidase (HPX) antiserum [1:50 dilution in phosphate-buffered saline with 2% (vol/vol) goat serum, 2 h at 4°] and followed, after washing, with fluorescein-labeled goat anti-rabbit IgG (1:100 dilution with 2% goat serum, 1 h at 4°C). Stained cells were visualized using a Zeiss LSM510 confocal microscope equipped with a Zeiss 63x oil immersion lens, numerical aperture 1.3. Results are representative from at least 80 cells from 3 different coverslips in 3 different experiments.
| RESULTS |
|---|
|
|
|---|
|
It is well known that the bursting pattern of electrical activity generates simultaneous [Ca2+]i oscillations in the whole islet of Langerhans (18, 19). Accordingly, when intracellular calcium was measured in intact islet, 17ß-estradiol did not induce any change in [Ca2+]i at substimulatory glucose concentrations. In marked contrast, when 17ß-estradiol was applied in the presence of a stimulatory concentration of glucose, a transitory peak of calcium followed by a repetitive pattern of [Ca2+]i oscillations on a plateau phase was elicited (
Fig. 1B). The frequency of [Ca2+]i oscillations was enhanced by 138 ± 33% (
Fig. 1C). Remarkably, in islets in which no [Ca2+]i oscillations were observed in the presence of 8.3 mM glucose, 17ß-estradiol triggered a repetitive oscillatory pattern (not shown). As a general rule, the lower the frequency of oscillations elicited by glucose, the higher the effect on both frequency and amplitude produced by 17ß-estradiol. Modulation of the calcium signals was not a sex-dependent effect, since it was observed in both male and female mice. Insulin secretion is a calcium-dependent process (20, 21); indeed, intracellular calcium oscillations generate an oscillatory pattern of insulin secretion (22, 23). In our case, insulin secretion was enhanced by 30 ± 10% when 17ß-estradiol was applied synergistically with 8.3 mM glucose. No significant effect was observed at higher glucose concentrations (
Fig. 1D).
As expected for a physiological modulator, the 17ß-estradiol potentiation of glucose effects was concentration dependent (
Fig. 2A, B),
with a half-maximal stimulatory concentration of about 500 pM, well within the physiological range. The response exhibited some pharmacological specificity, since the stereoisomer 17
-estradiol presented half the activity of 17ß-estradiol. Further selectivity of the system is manifested by the fact that other hormones with similar structures, such as testosterone and the 17ß-estradiol metabolite estriol, had a very reduced effect (
Fig. 2C). In summary, the relative potency for enhancing glucose-induced [Ca2+]i oscillations was in the following order: 17ß-estradiol, estrone >
-estradiol
testosterone, estriol.
|
We have also demonstrated that fast modulation of the glucose response by 17ß-estradiol is a nongenomic effect. Pretreatment for at least 3 h with actinomycin-D, an inhibitor of RNA synthesis, did not prevent the effect of 17ß-estradiol on [Ca2+]i (
Fig. 2D). When islets were incubated for 4 h in the presence of cycloheximide, a potent inhibitor of protein synthesis, 17ß-estradiol effects on intracellular calcium oscillations were unchanged (
Fig. 2D). Furthermore, tamoxifen, a classic inhibitor of the cytosolic/nuclear receptor, was without effect on 17ß-estradiol regulation of intracellular calcium, further excluding the involvement of the intracellular estrogen receptor (
Fig. 2E). Nonetheless, tamoxifen elicited a small change in the glucose-induced oscillatory pattern, acting as a weak agonist, although such a response was never large enough to mask 17ß-estradiol effects. Estradiol conjugated to BSA, which is not membrane permeable, was able to reproduce the effect of 17ß-estradiol on [Ca2+]i in the presence of stimulating glucose (
Fig. 2F).
The foregoing results strongly suggest the existence of a signal-generating receptor for 17ß-estradiol on the cell surface distinct from the classic cytosolic/nuclear steroid-receptor. Since the resting membrane potential in pancreatic ß-cells is governed mainly by KATP channels, the small depolarization elicited by 17ß-estradiol in the absence of glucose suggests an effect of 17ß-estradiol on KATP channel activity. To investigate this possibility, cell-attached and excised patch recordings were obtained from isolated ß-cells from mouse islet of Langerhans and maintained in cell culture for 1 to 3 days. When cell-attached recordings were obtained from isolated cells under conditions in which the bathing solution contained no glucose, physiological concentrations of 17ß-estradiol induced a substantial decrease in KATP channel activity (
Fig. 3A).
This response was gradual and completely reversible.
Figure 3B shows the time course of KATP mean open probability (NPo) when applying 100 pM 17ß-estradiol. The time to reach the maximum current inhibition after 17ß-estradiol application was 3 to 7 min, which was transitory: channel activity returned to control values in about 30 min even in the presence of 17ß-estradiol (not shown).
|
To further substantiate that these effects were mediated through a plasma membrane receptor, estradiol linked to BSA was tested under the same conditions. As with calcium signals, no significant differences were found between channel activity inhibition by 17ß-estradiol and estradiol conjugated to BSA. Moreover, application of 17ß-estradiol to the inner side of an excised membrane patch did not affect KATP channel activity, even at the highest dose examined (10 nM) (
Fig. 3C). These experiments indicate that 17ß-estradiol effects are initiated at the plasma membrane. Moreover, exposure to 17ß-estradiol induced a prolonged period of refractoriness to further estradiol stimulation (not shown). The existence of desensitization of the response after 20 min application of 17ß-estradiol is in accordance with the existence of a receptor responsible of the decrease in KATP channel activity. Such a receptor must be located at the plasma membrane because estradiol conjugated to BSA not only reproduces 17ß-estradiol signals, but also decreases KATP channel activity recorded in the cell-attached mode.
To further investigate the existence of an estrogen receptor at the membrane of pancreatic ß-cells, the experiment shown in
Fig. 4
was performed.
Figure 4A shows labeling of estradiol conjugated to HPX developed using diaminobenzidine. Binding of estradiolHPX appeared to be competitive, since it could be blocked by incubating in the presence 300-fold excess of 17ß-estradiol (
Fig. 4B). Nonetheless, it could be argued that estradiolHPX might enter through pores at the plasma membrane caused by paraformaldehyde fixation and binding to cytosolic/nuclear receptors.
Figure 4C, D illustrates that this is not the case. A dextran-TMR was used as a dye to demonstrate permeability of the plasma membrane when visualized using confocal microscopy. The molecular weight of this compound is 40,000, very similar to the 44,000 of estradiolHPX complex. In our hands, 98% of the cells were impermeable to dextran-TMR after paraformaldehyde treatment, which clearly demonstrates that estradiolHPX binds competitively to the plasma membrane. Furthermore, when confocal reflective microscopy was used, peroxidase labeling was visualized as a ring when a section through the middle of the cell was imaged (
Fig. 4E, F). Such a result clearly indicates that the DAB precipitate was located at the membrane. The experiment in
Fig. 4G shows the location of estradiolHPX via a double immunocytochemistry, where cells incubated with estradiolHPX as in
Fig. 4A were exposed to an antibody anti-HPX. A secondary antibody anti-IgG fluorescein conjugated was applied later. When cells were imaged through the center of the cell, staining was clearly seen only at the plasma membrane. These experiments clearly demonstrate that estradiolHPX has a high affinity binding site at the plasma membrane of pancreatic islet cells that can only be explained by the existence of an estrogen receptor.
|
| DISCUSSION |
|---|
|
|
|---|
The effect is partially stereospecific and is not reproduced by other estrogens of similar chemical structure such as estriol or testosterone. These results strongly suggest the existence of a receptor for 17ß-estradiol in pancreatic ß-cell. Such a receptor must be different from the classic cytosolic/nuclear receptor since the effect is nongenomic, as demonstrated by the lack of efficacy of RNA/protein synthesis inhibitors. Furthermore, steroid responses mediated by intracellular receptor occur with a latency of 12 h. The fast time course of the results presented here indicates that they are not mediated by a classical genomic mechanism. Moreover, tamoxifen, a classic antiestrogen, was without action in changing 17ß-estradiol responses.
The receptor responsible for the 17ß-estradiol effect should be located at the plasma membrane. E-BSA, which does not cross plasma membrane, mimics 17ß-estradiol actions both on calcium signals and KATP channel activity. A crucial issue is the mechanism by which 17ß-estradiol is exerting its effect, and several lines of evidence are consistent with the generation of an intracellular second messenger. First, there is a time delay between application of the steroid and changes in [Ca2+]i or channel activity. Second, 17ß-estradiol has no effect in excised patches. The reduction of KATP channel activity elicited by 17ß-estradiol is also a receptor-mediated process distinct from the more direct inhibitory action of sulfonyl-ureas on KATP channels. The latter rules out a direct binding of 17ß-estradiol to the KATP channel or to the sulfonylurea receptor, since sulfonylureas are able to block KATP channels in inside-out patches (24). We can conclude from these experiments that binding of 17ß-estradiol to its receptor will activate a second-messenger system, which regulates KATP channels. This second messenger acts in synergy with other intracellular channel regulators generated by glucose metabolism, as summarized in
Fig. 5.
|
The existence of a membrane receptor for estrogens is still a matter of controversy, but several works have demonstrated specific binding of 17ß-estradiol (26, 27) or have detected proteins in the plasma membrane that cross-react with an antibody raised against cytosolic classical estrogen receptor (28). One of the most powerful tools of receptor identification is specific antibody recognition. Due to the absence of antibodies to membrane estrogen receptors, we have used a new and simple ligand binding assay, combined with confocal reflective microscopy and immunofluorescence. We have been able to demonstrate with these techniques a specific binding site for 17ß-estradiol at the plasma membrane of acutely isolated cells.
In the endocrine pancreas (classically a nontarget tissue), the effect of estradiol was observed only during glucose stimulation, and not in basal conditions. Such a synergistic interaction indicates that 17ß-estradiol acts as a modulatory hormone: it enhances glucose responsiveness of pancreatic islet of Langerhans, yet is without effect in the absence of glucose. The effects presented on electrical activity, intracellular calcium, and insulin secretion suggest a potential role for 17ß-estradiol or some of its analogs as a treatment for non-insulin-dependent diabetes mellitus (NIDDM). Since 17ß-estradiol will enhance insulin secretion synergistically with a stimulatory glucose concentration, it would avoid hypoglycemia caused by sulfonylureas when taken in the absence of stimulatory glucose concentration. The insulinotropic action induced by 17ß-estradiol resembles that described for other modulators such as GLP-1 (29) and is in the range of other insulin secretion modulators such as vasoactive intestinal polypeptide (30) or gastrin-releasing peptide (31). GLP-1 has been proposed as an alternative treatment to sulfonylureas for NIDDM due to its synergistic effect with glucose. The synergistic effect of 17ß-estradiol with glucose described in this work may open up the possibility of a new treatment for NIDDM based on the use of estrogens as modulators of insulin secretion via a plasma membrane receptor.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
2 Abbreviations: TMR, tetramethylrhodamine; DMSO, dimethyl sulfoxide; BSA, bovine serum albumin; NIDDM, non-insulin-dependent diabetes mellitus; DAB, diaminobenzidine. ![]()
Received for publication February 19, 1998. Accepted for publication June 4, 1998.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Gilad and B. Schwartz Association of estrogen receptor {beta} with plasma-membrane caveola components: implication in control of vitamin D receptor J. Mol. Endocrinol., June 1, 2007; 38(6): 603 - 618. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vital, E. Larrieta, and M. Hiriart Sexual dimorphism in insulin sensitivity and susceptibility to develop diabetes in rats. J. Endocrinol., August 1, 2006; 190(2): 425 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Le May, K. Chu, M. Hu, C. S. Ortega, E. R. Simpson, K. S. Korach, M.-J. Tsai, and F. Mauvais-Jarvis Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice PNAS, June 13, 2006; 103(24): 9232 - 9237. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zsarnovszky, H. H. Le, H.-S. Wang, and S. M. Belcher Ontogeny of Rapid Estrogen-Mediated Extracellular Signal-Regulated Kinase Signaling in the Rat Cerebellar Cortex: Potent Nongenomic Agonist and Endocrine Disrupting Activity of the Xenoestrogen Bisphenol A Endocrinology, December 1, 2005; 146(12): 5388 - 5396. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Choi, J. S. Jang, and S. Park Estrogen and Exercise May Enhance {beta}-Cell Function and Mass via Insulin Receptor Substrate 2 Induction in Ovariectomized Diabetic Rats Endocrinology, November 1, 2005; 146(11): 4786 - 4794. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Bulayeva, A. L. Wozniak, L. L. Lash, and C. S. Watson Mechanisms of membrane estrogen receptor-{alpha}-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E388 - E397. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. V. Chaban, A. J. Lakhter, and P. Micevych A Membrane Estrogen Receptor Mediates Intracellular Calcium Release in Astrocytes Endocrinology, August 1, 2004; 145(8): 3788 - 3795. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Soria, I. Quesada, A. B. Ropero, J. A. Pertusa, F. Martin, and A. Nadal Novel Players in Pancreatic Islet Signaling: From Membrane Receptors to Nuclear Channels Diabetes, February 1, 2004; 53(90001): S86 - 91. [Abstract] [Full Text] |
||||
![]() |
A. M. Braun and P. Thomas Androgens Inhibit Estradiol-17{beta} Synthesis in Atlantic Croaker (Micropogonias undulatus) Ovaries by a Nongenomic Mechanism Initiated at the Cell Surface Biol Reprod, November 1, 2003; 69(5): 1642 - 1650. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Booth, M. Marchesi, E. J. Kilbourne, and B. R. Lucchesi 17{beta}-Estradiol as a Receptor-Mediated Cardioprotective Agent J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 395 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Papakonstanti, M. Kampa, E. Castanas, and C. Stournaras A Rapid, Nongenomic, Signaling Pathway Regulates the Actin Reorganization Induced by Activation of Membrane Testosterone Receptors Mol. Endocrinol., May 1, 2003; 17(5): 870 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Kalish, E. Barrett-Connor, G. A. Laughlin, and B. I. Gulanski Association of Endogenous Sex Hormones and Insulin Resistance among Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Intervention Trial J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1646 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Quesada, J. M. Rovira, F. Martin, E. Roche, A. Nadal, and B. Soria Nuclear KATP channels trigger nuclear Ca2+ transients that modulate nuclear function PNAS, July 9, 2002; 99(14): 9544 - 9549. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Ropero, B. Soria, and A. Nadal A Nonclassical Estrogen Membrane Receptor Triggers Rapid Differential Actions in the Endocrine Pancreas Mol. Endocrinol., March 1, 2002; 16(3): 497 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bosch, M. J. Kelly, and O. K. Ronnekleiv Distribution, Neuronal Colocalization, and 17{beta}-E2 Modulation of Small Conductance Calcium-Activated K+ Channel (SK3) mRNA in the Guinea Pig Brain Endocrinology, March 1, 2002; 143(3): 1097 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Gruber, W. Tschugguel, C. Schneeberger, and J. C. Huber Production and Actions of Estrogens N. Engl. J. Med., January 31, 2002; 346(5): 340 - 352. [Full Text] [PDF] |
||||
![]() |
A. Nadal, M. Diaz, and M. A. Valverde The Estrogen Trinity: Membrane, Cytosolic, and Nuclear Effects Physiology, December 1, 2001; 16(6): 251 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B. Wade, S. Robinson, R. A. Shapiro, and D. M. Dorsa Estrogen Receptor (ER){{alpha}} and ER{beta} Exhibit Unique Pharmacologic Properties When Coupled to Activation of the Mitogen-Activated Protein Kinase Pathway Endocrinology, June 1, 2001; 142(6): 2336 - 2342. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. M. Benten, C. Stephan, M. Lieberherr, and F. Wunderlich Estradiol Signaling via Sequestrable Surface Receptors Endocrinology, April 1, 2001; 142(4): 1669 - 1677. [Abstract] [Full Text] |
||||
![]() |
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling Multiple Actions of Steroid Hormones---A Focus on Rapid, Nongenomic Effects Pharmacol. Rev., December 1, 2000; 52(4): 513 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nadal, A. B. Ropero, O. Laribi, M. Maillet, E. Fuentes, and B. Soria Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta PNAS, October 10, 2000; 97(21): 11603 - 11608. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Jiao, P. Baumann, A. Baron, A. Roatti, R. A. Pence, and A. J. Baertschi Sulfonylurea receptor ligands modulate stretch-induced ANF secretion in rat atrial myocyte culture Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2028 - H2038. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Salhab, P. W. Shaul, B. E. Cox, and C. R. Rosenfeld Regulation of types I and III NOS in ovine uterine arteries by daily and acute estrogen exposure Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2134 - H2142. [Abstract] [Full Text] |